Broadens BiondVax’s global intellectual property portfolio
NESS ZIONA, ISRAEL, January 27, 2016 –
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled “Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines” has completed examination and is allowed for issuance as a patent.
The invention covers the use of BiondVax’s universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax’s completed clinical trials have shown significantly increased effectiveness against multiple flu strains.
Ron Babecoff, CEO of BiondVax commented, “Current flu vaccines are strain specific and are not particularly effective against circulating ‘wild-type’ strains due to mismatches. In fact, last year’s seasonal flu vaccine was only 23% effective1. Conversely, our vaccine provides long-lasting and higher effectiveness against multiple flu strains.”
Continued Dr. Babecoff, “Our newly approved US patent demonstrates the novel nature of our vaccine technology and strengthens our IP portfolio for many years to come.”
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.